Drug Enforcement Administration Mid-level Practitioner Regulation

Key words: Drug Enforcement Administration, mid-level practitioners, prescriptive authority.

The U.S. federal Drug Enforcement Administration (DEA) published a final regulation on June 1, 1993, regarding registration of so-called mid-level practitioners (MLPs). The regulation requires an MLP who “dispenses” controlled substances to register with the DEA unless the MLP is exempt as an agent or employee of a DEA registrant such as a hospital or physician.

In a June 18, 1993, meeting with AANA representatives, the DEA assured the AANA that most nurse anesthetists (CRNAs) would not have to register with the DEA as they would typically be considered agents or employees of DEA registrants.

On the other hand, CRNAs who practice in the handful of states (e.g., New Hampshire) in which CRNAs have authority to prescribe controlled substances must register with the DEA as an MLP in order to exercise that authority.

A summary of the AANA's June 18, 1993, meeting with the DEA is on the following page. The DEA has reviewed the summary and acknowledged that it is an accurate description of our meeting.

The summary sets forth the DEA's views concerning the MLP regulation's effect concerning CRNAs.

July 1992 DEA proposed regulations

On July 29, 1992, the DEA proposed new regulations creating the classification of “Mid-Level Practitioner (MLP).” An MLP was defined to mean an individual practitioner “other than a physician, dentist . . . veterinarian . . . or podiatrist, who is licensed, registered, or otherwise permitted in the United States or the jurisdiction in which he/she practices, to dispense a controlled substance in the course of professional practice.”

The proposed MLP regulations applied to more practitioners than just those who prescribe a controlled substance. A mid-level practitioner is one authorized to “dispense” controlled substances. In the introduction that preceded the proposed MLP regulation, the DEA stated that “dispense” included either “prescribing” or “administering.” In a previous version of the DEA regulation, the DEA had acknowledged that nurse anesthetists, in their traditional areas of practice, did not typically “prescribe” within the meaning of federal law. However, nurse anesthetists administer controlled substances every day.
Summary of Drug Enforcement Administration Mid-level Practitioner Regulations

On June 18, 1993, representatives of the American Association of Nurse Anesthetists (AANA) met with the Drug Enforcement Administration (DEA) in Washington, DC and were assured that most Certified Registered Nurse Anesthetists (CRNAs) would be exempt from registration under the DEA's newly issued regulations concerning mid-level practitioners (MLPs).

On June 1, 1993, the DEA published regulations in the Federal Register defining mid-level practitioners as "an individual practitioner . . . , other than a physician, dentist, veterinarian, or podiatrist, who is licensed, registered, or otherwise permitted by the United States or the jurisdiction in which he/she practices, to dispense a controlled substance in the course of professional practice."

The DEA is defining "dispense" to include "administration," "prescribing" or both. Because almost every nurse anesthetist administers controlled substances, nurse anesthetists, even those who have no prescriptive authority, would be "mid-level practitioners" as that term is defined by the DEA. On the basis of past meetings with the DEA, the AANA believed that most nurse anesthetists would be exempt from registration because they were "agents" or "employees" of DEA registrants. However, the AANA was concerned about the status of CRNAs who are not employees of physicians or hospitals but act as "independent contractors," including those who work as locum tenens or moonlight. On June 18, 1993, AANA representatives met with the DEA in Washington, DC and were assured that most Certified Registered Nurse Anesthetists (CRNAs) would be exempt from the registration requirement as "agents" of DEA registrants even if their employment status was best described as being "independent contractors."

At the meeting, the DEA explained that the DEA's main responsibility in this area is to safeguard against the diversion of controlled substances. The DEA will treat CRNAs as "agents" of DEA registrants if the CRNAs are subject to whatever controls and procedures the particular DEA registrant has adopted to guard against diversion of controlled substances. Under existing DEA regulations, all DEA registrants are obligated to adopt these controls and procedures. The requirement can be found in 21 CFR 1301.71. DEA will not require additional controls or procedures for CRNAs to be considered agents of DEA registrants. Moreover, it will not be necessary for CRNAs to actually have contracts or particular terms in contracts to be considered agents and, therefore, exempt.

DEA has provided the following three examples illustrating whether or not CRNAs would be entitled to the exemption for employees and agents:

1. A CRNA is employed by a registrant, either a practitioner or a hospital/clinic, and in the normal course of employment, administers or dispenses controlled substances from the registrant's supplies. As an employee of a registrant acting in the normal course of employment, the CRNA would be exempt from the registration requirement.

2. A CRNA, other than as an employee of a registrant, is allowed by a registrant to administer or dispense controlled substances in the normal course of practice from the registrant's supplies. The CRNA is, for purposes of the regulations, an agent of the registrant and is not subject to the registration requirement.

3. A CRNA must individually obtain a personal supply of controlled substances from which he or she administers or dispenses. In this case, DEA registration is required because the individual is administering or dispensing controlled substances from personal supplies rather than from the supplies of another registrant.

The DEA stated that it did not intend to affect CRNA practice settings and that it expected very few CRNAs to have to register in order to continue practicing as they have been practicing. This interpretation is important because after July 1, 1993, practitioners who administer controlled substances (whether or not they have prescriptive authority) must be DEA-registered unless they are exempt.

The new regulation also provides that the exemption for registration for employees or agents of DEA registrants would not be available for employees and agents of mid-level practitioners. The DEA confirmed that this regulation would not, for example, affect nurse anesthetists who write medication orders for hospital- or physician-employed nurses to administer. In these circumstances, the nurse administering the medication will continue to operate as the agent or employee of the DEA-registered hospital or physician not the CRNA. Thus, the adoption of the new regulation should not affect the ability of nurse anesthetists to continue to write orders for drugs to be administered by other nurses.

This summary of the meeting of June 18, 1993, has been reviewed by the representatives of the Drug Enforcement Administration with whom the AANA met, who have authorized the AANA to state that it constitutes a correct summary of our meeting and of the views of the staff of the Drug Enforcement Administration.

July 1, 1993
DEA regulations exempt from registration those MLPs who administer and dispense (other than by issuance of prescription) controlled substances as the agent or employee of another practitioner, other than an MLP, registered to dispense controlled substances. If a CRNA were not covered by this exemption, the CRNA seemingly would have to register with the DEA even if the CRNA merely administered controlled substances and did not "prescribe."

The DEA included a paragraph in the introduction to the regulations that specifically addressed CRNAs:

"It should be noted that practitioners in institutional settings who issue orders for medications for direct administration to a patient, such as nurse anesthetists in the normal course of their practice, are not prescribing within the meaning [of 21 CFR 1306.02(e)]. and would be exempt from registration. In that context, DEA neither requires nor encourages registration for MLPs acting as agents of other registrants."

The DEA's comment was based in part on language that the AANA suggested for an earlier version of the DEA regulation which would have required practitioners who prescribed to register. The thrust of the DEA's regulations changed so radically, however, from registration based on prescribing to registration based on dispensing which included administration that the AANA did not believe that the comment adequately addressed the position of CRNAs. The exemption for CRNAs seemed to be based on "agency" rather than the DEA's previous acknowledgment that CRNAs do not prescribe within the meaning of federal law.

Consequently, on September 25, 1992, the AANA submitted comments regarding the proposed DEA regulation. The AANA pointed out that the DEA had never previously required registration of those who administered and suggested that the DEA exempt from registration those practitioners who administer but do not prescribe (within the meaning of CFR 1306.02(f)) controlled substances. Alternatively, if the DEA was not willing to provide that those who merely administer should be exempt, the AANA asked the DEA to clarify its exemption for agents and employees. The AANA pointed out that there were more than 2,400 CRNAs who identified themselves as independent contractors and who were not employees of hospitals or physicians.

In addition, the AANA objected to other provisions in the proposed regulation. The AANA felt that the phrase "mid-level practitioner" implied that these practitioners provided a different and presumptively lesser level of care than practitioners who were previously entitled to DEA registration. The AANA objected to the DEA's proposed requirement that MLPs who registered maintain protocols, practice guidelines, agreements, and other documents required by the state describing the conditions and extent of authorization to "dispense" controlled substances. Most states do not require such documentation and practitioners could have difficulty convincing a DEA inspector that they had authority to engage in long-accepted practices for which there might be little documentation available.

June 1993 DEA final regulation and AANA meeting with the DEA

The DEA revised the MLP regulations that were proposed July 29, 1992, and issued a final regulation on June 1, 1993. While some of the AANA's minor comments were accepted, the language of the draft regulations requiring registration of those who administer, not just those who prescribe, remained unchanged.

Regarding the AANAs concern about the status of independent contractors, the introduction to the regulations stated that:

"DEA cannot provide a general response regarding circumstances involving the conditions of specific contracts. In cases other than those in which the contract specifies the individual will act as an agent of the registrant, the exemption from the registration requirement will depend upon the specific conditions under which the individual will handle controlled substances."

CRNAs who act as independent contractors will rarely, if ever, have contracts that provide that the CRNA is an agent of a DEA registrant. What circumstances was the DEA looking for to find that CRNAs who are independent contractors were exempt from registration? The AANA requested a meeting with the DEA to find out; the results are described in the summary of the meeting in this article.

After reviewing the DEA's interpretation of its final MLP regulation, some might ask how an independent contractor can be an agent and therefore exempt from DEA registration for purposes of controlled substances utilization and yet still be an independent contractor for purposes of employment or negligence actions.

The answer is that a CRNA can be an "agent" for some purposes without being an "agent" for all purposes. As the summary of the AANA's meeting

---

1. 21 CFR 1306.02(f) defines the term "prescription" as follows: "The term 'prescription' means an order for medication which is dispensed to or for an ultimate user but does not include an order for medication which is dispensed for immediate administration to the ultimate user(s) (e.g., an order to dispense a drug to a bed patient for immediate administration in a hospital is not a prescription)"
with the DEA indicates, if a CRNA who is otherwise an independent contractor is subject to whatever controls and diversion of controlled substances, the CRNA will be deemed an "agent" of the DEA registrant, avoiding the need to register as an MLP. However, just because the CRNA is subject to controls and procedures against theft of controlled substances and is deemed an "agent" by the DEA does not mean that the CRNA must be regarded as subject to the registrant's control concerning the administration of controlled substances for purposes of negligence law.

In most states, a person is liable for the negligence of another only if the person controlled the procedure that gave rise to the negligence. A hospital may require that anyone withdrawing drugs from the hospital pharmacy must follow certain procedures for signing out controlled substances, accounting for use, returning unused portions, and other matters relating to drug use. The hospital does not, however, have to control the manner in which a CRNA who is an independent contractor selects controlled substances, determines dosages, and physically administers them. Thus, the CRNA would be deemed an "agent" of a hospital for purposes of obtaining controlled substances but might not be the "agent" of the hospital in the area of malpractice liability.

At its June meeting with the AANA, the DEA was clear that very few CRNAs would have to register as MLPs. The AANA intends to continue its dialogue with the DEA to assure that the DEA's activities do not affect legitimate and well-accepted healthcare practices or unfairly restrict CRNA activities.

Complying with the DEA's new MLP regulation

Section 1301.24(b) of the DEA's regulations provides an exemption for:

"[A]n individual practitioner... who as an agent or employee of another practitioner (other than a mid-level practitioner) registered to dispense controlled substances may, when acting in the usual course of his/her employment, administer and dispense (other than by issuance of prescription) controlled substances if and to the extent that such individual practitioner is authorized or permitted to do so by the jurisdiction in which he/she practices, under the registration of the employer or principal practitioner in lieu of being registered him/herself. (For example, a staff physician employed by a hospital need not be registered individually to administer and dispense, other than by prescribing, controlled substances within the hospital.)"

Consequently, if a CRNA does not prescribe, and if the CRNA is an agent or employee of a DEA registered practitioner (such as a hospital, an anesthesiologist or a surgeon) the CRNA does not have to register with the DEA as an MLP.

What about a CRNA who is an independent contractor and not an employee of a DEA registered practitioner? As long as the CRNA is subject to whatever controls and procedures a DEA registrant has adopted to guard against diversion of controlled substances, the CRNA will be deemed to be the agent of the DEA registrant and will be permitted to administer controlled substances without having to personally register. Because all DEA registrants are required by law to have such controls and procedures, the agency exemption should apply to virtually all CRNA independent contractors. Both the AANA and the DEA believe that very few CRNAs will have to register with the DEA in order to continue practicing as they have been practicing.

For those CRNAs who either are not agents or employees of other DEA registrants, or have and utilize prescriptive authority for controlled substances under state law, registration will be required as an MLP. According to the DEA regulation, those MLPs who are now registered with the DEA will have their registrations converted to the MLP category by no later than December 31, 1993. The regulations provide that conversion will be accomplished by the assignment of a new registration number under the MLP format and the issuance of a new registration certificate. Upon receipt of their new certificates, MLPs will be required to return their old registration certificates to the DEA. The DEA has stated that it will give affected registrants advance notice of the conversion of their numbers. The authority of MLPs to handle controlled substances will not be affected by the conversion.

For those MLPs who register or whose registration is converted to MLP status, the new regulations require MLPs to:

"... maintain in a readily retrievable manner those documents required by the state in which he/she practices which describe the conditions and extent of his/her authorization to dispense controlled substances and shall make such documents available for inspection and copying by authorized employees of the [DEA]. Examples of such documentation include protocols, practice guidelines or practice agreements."

The DEA has not yet offered any advice on what documentation it expects regarding evidence.

---

2. A DEA registrant is not necessarily an individual. Hospitals and ambulatory surgery centers, for example, are typically DEA registrants. A nurse anesthetist in a hospital, therefore, would typically be acting as the hospital's agent regarding handling of controlled substances, rather than an individual physician.
of authority. When CRNAs are granted prescriptive authority in a state, the authority is likely to be clearly stated in the state's nurse practice act and/or board of nursing regulations. In a more traditional area of practice, such as administration of controlled substances, it is less clear what documentation would satisfy the DEA if a CRNA wanted to register with the DEA in connection with this activity alone. Some states merely recognize nurse anesthesia practice without specifically delineating CRNA scope of practice. The AANA is attempting to obtain clarification of this point from the DEA. However, if all a CRNA is doing is administering controlled substances, the lack of clarity in required documentation is one reason why it is hard to see any benefit in registration.

For those CRNAs who register, the registrant is required to provide effective controls and procedures to guard against theft and diversion of controlled substances. All controlled substances must be stored in a securely locked, substantially constructed cabinet, and no registrant may employ anyone who will have access to controlled substances if that person has had his or her application for registration denied or revoked. There are substantial reporting requirements. Biannual inventories must be taken, and extensive record keeping requirements exist for all controlled substances which are sorted or dispensed.

The AANA believes that CRNAs who are merely engaging in traditional activities such as administration of controlled substances would not benefit from registering with the DEA. Registration would merely impose upon such CRNAs the obligation to maintain documentation and other requirements that the DEA is imposing on MLP registrants. In addition, CRNAs must understand that DEA registration does not confer upon the registrant authority beyond that granted by state law. For example, suppose a CRNA practices in a state that allows CRNAs to administer controlled substances but does not grant CRNAs prescriptive authority. While such a CRNA could register with the DEA, registration would not allow the CRNA to prescribe.

On the other hand, a CRNA who practices in a state that gives CRNAs authority to prescribe controlled substances (e.g., Alaska, New Hampshire, and Montana) must register with the DEA to exercise that authority.

---

**MERCY Hospital of Williston**

**CERTIFIED REGISTERED NURSE ANESTHETIST**

Warm friendly people, low crime rate, good hunting and fishing, excellent school system and 123 acute-bed hospital offering all specialties except open heart and neuro is what you will find with employment at Mercy Hospital of Williston, North Dakota.

Williston is located 18 miles east of the Montana state line and 60 miles south of the Canadian border in a community of approximately 13,000. Full-time position available for Staff CRNA to join the team of two anesthesiologists and 4 full-time CRNAs. Salary is commensurate with experience.

Relocation Bonus, Interview Expense, Moving Allowance, Health and Life Insurance, Pension Plan, Paid Annual Leave, Continuing Education, etc.

For additional information, or to apply contact: Janice Arnson, Director of Human Resources, Mercy Hospital, 1301 15th Avenue West, Williston, ND 58801, or telephone: 701-774-7454.

This institution is an affiliate of Catholic Health Corporation, Omaha, Nebraska. We are an EOE.
A Single Agent for Virtually All Procedures

- Predictable, dose-dependent clinical duration\(^1,2\)
- No cumulative effects even after 10 hours of 1.1 \(\mu\)g/kg/min infusion\(^3\)
- Hemodynamic stability throughout the entire dosing range\(^1,2,4\)
- Excellent safety profile in a wide range of patients\(^5,7\)

Please see following page for brief summary of prescribing information.


© 1993 ORGANON INC. ORG-15712 PRINTED IN USA FEBRUARY 1993
Norcuron®
(vecuronium bromide) for injection

Before prescribing, please consult complete product information, a summary of which follows:

**THESE DRUGS SHOULD BE ADMINISTERED BY ADEQUATELY TRAINED INDIVIDUALS FAMILIAR WITH ITS ACTIONS, CHARACTERISTICS, AND HAZARDS.**

**CONTRAINDICATIONS:** Norcuron® contained in vials or in prefilled syringes is contraindicated in patients who have shown a hypersensitivity to its ingredients. Norcuron® should not be used in the treatment of status asthmaticus as it may enhance bronchial smooth muscle tone, thus precipitating a bronchospasm.

**WARNINGS:** The prescriber should remain aware of the following:

- **Hypersensitivity:** Cross-sensitivity may exist among the long-acting muscle relaxants. The patient should be observed for signs and symptoms of an allergic reaction and treated appropriately.

- **Neuromuscular Function:** The use of Norcuron® for intubation in patients with normal neurovascular function in whom an adequate incision can be made. If intubation cannot be performed, an anesthetist should be consulted immediately.

- **Monitoring of Neuromuscular Function:** Patients with known myasthenia gravis should be monitored carefully during and after surgery. The activity of the muscles innervated by the facial nerve should also be observed during administration of Norcuron®.

- **Respiration:** Adequate ventilation must be maintained throughout surgery. Cardiac arrhythmias may result from increased vagal tone with resultant bradycardia. The administration of Norcuron® may enhance these arrhythmias. In cardiac surgical patients, heparin may be used instead of dextrose in water (D) for injection to minimize the risk of cardiovascular depression.

- **Intubation:** It is recommended that the segment be used in the form of a bolus injection only. Continuous infusions are contraindicated for intubation purposes.

- **Respiratory Distress:** Respiration should be monitored carefully, and artificial ventilation should be provided if necessary. The respiratory rate, minute volume, and tidal volume should be closely observed, and any signs of respiratory depression monitored.

- **DOSAGE AND ADMINISTRATION:** The use of Norcuron® for intubation should be limited to patients with normal neurovascular function. The drug should not be used in the treatment of status asthmaticus as it may enhance bronchial smooth muscle tone, thus precipitating a bronchospasm.

- **INCOMPATIBILITY:** Norcuron® should be administered in a manner that avoids contact with other drugs, solutions, or equipment, except as directed by the manufacturer. Norcuron® should not be administered in the same line as other drugs.

- **compatibility:** Norcuron® should not be mixed with other drugs, solutions, or equipment, except as directed by the manufacturer. Norcuron® should not be administered in the same line as other drugs.

- **Storage and Stability:** Norcuron® should be refrigerated at 2-8°C (36-46°F) in the original container. After 24 hours, the drug should be discarded. Norcuron® should be discarded if the vial is punctured or if the solution is cloudy, discolored, or contains particulate matter. Norcuron® should be used within 24 hours of opening the vial.

- **ADVERSE REACTIONS:** The most frequently used dose of Norcuron® is 60 mg (6 mg/mL) diluted in 50 mL of saline or 0.9% sodium chloride injection to a final concentration of 1.2 mg/mL. The dose is repeated at intervals of 5-10 minutes as needed.

- **Dosage in Children:** The dose of Norcuron® should be based on body weight, age, and type of surgery. The dosage in children should be adjusted to achieve a muscle twitch response. The initial dose of Norcuron® in children should be 0.01 mg/kg, and subsequent doses should be increased by 0.01 mg/kg at 5-minute intervals until a satisfactory intubation condition is obtained. The maintenance dose should be given every 10-15 minutes. The duration of action of Norcuron® is approximately 90 minutes in adults and 120 minutes in children.

- **DOSAGE IN PATIENTS WITH ALTERED HEPATIC FUNCTION:** In patients with hepatic impairment, the dosage of Norcuron® should be reduced to 0.0075 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED RENAL FUNCTION:** In patients with renal impairment, the dosage of Norcuron® should be reduced to 0.005 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED AGE AND SEX:** In elderly patients, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BMI:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY WEIGHT:** In patients with body weight less than 50 kg, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.

- **DOSAGE IN PATIENTS WITH ALTERED BODY MASS INDEX:** In patients with body mass index (BMI) greater than 30, the dosage of Norcuron® should be reduced to 0.006 mg/kg to ensure adequate neuromuscular blockade.
Auto Setup

Selected configuration automatically sets predetermined choices for Alarm Limits, Trend Duration, Alert Zone Widths, and Manual Setup

<table>
<thead>
<tr>
<th>Date Saved</th>
<th>Ohmeda Default</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mar-10-93 1.</td>
<td>INDUCTION</td>
</tr>
<tr>
<td>Mar-10-93 2.</td>
<td>MAINTENANCE</td>
</tr>
<tr>
<td>Mar-10-93 3.</td>
<td>EMERGENCE</td>
</tr>
<tr>
<td>Mar-10-93 4.</td>
<td>NEONATE</td>
</tr>
<tr>
<td>Mar-10-93 5.</td>
<td>PED INDUCTION</td>
</tr>
<tr>
<td>Mar-10-93 6.</td>
<td>PED MAINTENANCE</td>
</tr>
<tr>
<td>Mar-10-93 7.</td>
<td>EYE CASE</td>
</tr>
<tr>
<td>Mar-10-93 8.</td>
<td>TRAUMA</td>
</tr>
<tr>
<td>Mar-10-93 9.</td>
<td>ADULT COPD</td>
</tr>
<tr>
<td>Mar-10-93 10.</td>
<td>ADULT ARDS</td>
</tr>
<tr>
<td>Mar-10-93 11.</td>
<td>BYPASS</td>
</tr>
<tr>
<td>Mar-10-93 12.</td>
<td>MAC</td>
</tr>
</tbody>
</table>


Think of how helpful it would be if you could pre-determine alarm limits, recorder settings and monitor parameters by procedure, patient type or phase of anesthesia before entering a case. And then activate them on command. That’s exactly what you can do with the Modulus CD-CV Anesthesia System’s autoconfiguration capability. You can establish 12 clinical groupings, preset up to 112 values in each one and recall them instantly — with the turn of a knob.

You could, for example, define groups for induction, maintenance and emergency. Then when you start your case, set the autoconfig system to induction and recall wide monitoring ranges so you can attend to intubation. In maintenance, you might program the alarm limits to tighter ranges. And at emergency, you could preset the system to switch off potential nuisance alarms.

All this is possible because physiologic and machine monitors are controlled by an interrelated management system.

To learn more about the Modulus CD-CV, contact your Ohmeda representative or call 1-800-345-2700.

Dedicated to Anesthesia and Critical Care

OHMEDA

© 1993 Ohmeda Inc
Anatomy of a Bair Hug™

Guaranteed Results
We guarantee that your patient will leave the OR normothermic.

Hugs!
Patented asymmetrical design arches to hug patient. Air holes wrap around to keep warm air close to patient’s skin.

Patented Central Manifold
Ensures even and safe heat distribution to trunk and vital organs.

Fixed Hose Length
Ensures predictable heat delivery to patient.

Arm Tuck
“Snugs” around patient’s arms to preserve warmth.

Simple to Use Temperature Control Panel
LED display with soft-touch controls allow better visibility in low light conditions.

New! Dual Ports
Allows easy access from both sides of table.

30% Lower Loft
Increases visibility.

Lifetime Warranty
For normal use. No exceptions. No excuses.

New! Retractable Handle
Allows you to move the Unit around easily without stooping.

The tissue in our Bair Hugger® Blankets is made from 30% post consumer waste paper. We have also reduced the amount of polyethylene in our Upper Body Blankets by 65%. Carbon, water and carbon dioxide are the principal by-products when Bair Hugger Warming Blankets are burned, so they can be incinerated safely.
The Best CRNA's Deserve MAXIMUM FLEXIBILITY.

Declare Your Independence!
The varied caseload you’ll find at Baylor, with nearly 300,000 annual admissions, will challenge your skills. Unsurpassed educational and research opportunities will broaden your knowledge. If you have the discipline to function as an independent practitioner, we’ll give you all the flexibility you need to take your career where you want it to go.

The Decisions Are Up To You.
Our flexible scheduling and benefits let you design the package that best suits your personal needs. And with our variety of free educational and professional growth programs, you chart the career path that’s right for you:

- AANA CE's available annually in-house, fee-paid
- TANA District #3 Continuing Education Programs, fee-paid
- AANA Dues Paid

State-Of-The-Art Technology.
Standardized rooms provide the finest in equipment technology. Utilizing the latest drugs the market has to offer, you’ll work with a variety of cases including: • Trauma • General • Regional • Blocks • Invasive Monitoring

What else does one of the largest teaching hospitals in Texas have to offer CRNA's? The chance to live in Dallas, a sophisticated, cosmopolitan city with a temperate climate. Excellent salaries made more so through the absence of city or state income taxes. Interview and relocation assistance. A VHA affiliated hospital with nationwide transferrable benefits. And more importantly, a chance to be the best. If that's what you want out of your career, you belong at Baylor.

To find out more about CRNA opportunities, call Kim Krause, CRNA Recruiter at (214) 820-6872 or Carol Fabrizio, CRNA, MHS, Chief CRNA at (214) 820-2165, 8 am - 4 pm, Monday-Friday.

Baylor University Medical Center
An Affiliate of the Baylor Health Care System

3500 Gaston Avenue, Dallas, Texas 75246
An equal opportunity employer. Baylor is a smoke-free workplace. © 1993 Baylor Health Care System
"My civilian anesthesia program was very demanding in terms of time and academics. It was impossible to have an outside job. My days were spent in the O.R. or in class, and frequent night call was required.

"When I heard about the Army Reserve STRAP program, I knew I could benefit from it. The program paid me a stipend of $794.00 per month for serving two days a month plus two weeks annual training.

"Also, they will pay for you to attend professional meetings for continuing education, and up to $3,000 a year on qualifying student loans.

"I was surprised by the level of instruction and O.R. experience I gained on my drill weekends. During my annual training I have the opportunity to expand my practice. I am able to learn spinal and regional anesthesia techniques. In civilian hospitals, this may not be possible.

"More people should consider the Army Reserve, not just for anesthesia, but for nursing in general."

2nd Lt. Colleen Kloehn, 44th General Hospital, Madison, WI.
Safe, Proven Relief

Effective Analgesia for Moderate Acute Pain

- Rapid, dependable pre- and post-op analgesia.
- Established safety for mother and child during labor and delivery.¹
- Indicated as an adjunct to regional anesthesia.²

For any questions, call 1-800-332-2056

Please see following page for a Brief Summary of the Prescribing Information.

The adverse experiences described below are based on data from short- and long-term clinical trials any route were those commonly

A total of 2446 patients were studied in butorphanol clinical trials. Approximately half received

Although there have been rare reports of infant respiratory distress/apnea following administration of

There

potential to butorphanol. However, pregnant rats treated subcutaneously with butorphanol at 1mg/kg

Pregnancy

uled DNA synthesis and repair assays conducted in cultured human fibroblast cells.

result in increased central nervous system depressant effects.

tral nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may

the possibility that a smaller initial dose and longer intervals between doses

phanol should

 Because butorphanol may increase the work of the heart,

Butorphanol may produce respiratory depression,

and alterations in mental state that would obscure the interpretation of the clinical course of patients with

Although the mixed agonist-antagonist opioid analgesics, as a class, have lower abuse potential than morphine, all such drugs can and have been reported to be abused.

Chronic use of STADOL* (butorphanol tartrate) Injectable has been reported to result in mild with-drawal symptoms, and reports of overuse and self-reported addiction have been received.

In cases where patients who used butorphanol chronically for up to 3 months, 7% had behavioral symptoms suggestive of possible abuse. Approximately 1% of these patients reported significant adverse symptoms such as nausea, vomiting, and diarrhea. None of these patients had overt evidence of opioid withdrawal occurred in 2 patients who stopped the drug abruptly after using 16 mg a day or more for longer than 3 months.

Special care should be exercised in administering butorphanol to emotionally unstable patients and to those with a history of drug misuse. When long-term therapy is necessary, such patients should be closely supervised.

The clinical manifestations of overdose are those of opioid drugs, the most serious of which are hypotension, cardiovascular collapse, and respiratory depression. Overdose can occur due to accidental or intentional misuse of butorphanol, especially in young children, who may gain access to the drug in the home.

The most frequently reported adverse experiences across all clinical trials with STADOL injectable and STADOL NS were somnolence (43%), dizziness (13%), nausea and vomiting (12%), in long-term trials with STADOL NS only, nasal congestion (13%) and insomnia (11%) were frequently reported.

The following adverse experiences were reported at a frequency of 1% or greater, and were consid-

Body as a whole: asthenia/lethargy*, headache', drowsiness, chills.

NERVOUS: anxiety, confusion*, dizziness (10%), euphoria, floating feeling, INSOMNIA (11%), ner-

RESPIRATORY: BRONCHITIS, COUGH, DYSPEPSIA*, 4ERXAS*, NASAL CONGESTION (13%), NASAL IRRITATION*, PHARYNGITIS*, RHINITIS, SINUS CONGESTION, SINUSITIS, UPPER RES-

CARDIOVASCULAR: VASODILATION*, PALPITATIONS

In patients with severe hepatic or renal disease the initial dosage interval for STADOL injectable should be increased.

severity and response has been well characterized. Subsequent dose levels should be determined by patient response rather than being scheduled at fixed intervals (see INDIVIDUALIZATION OF DOSAGE in full prescribing information).

DROPCOUNTAGE ON NARCOTICS

Because of its opioid antagonist properties, butorphanol is not recommended for use in patients

The occurrence of any side effects with butorphanol by

Factors to be considered in determining the dose are age, body weight, physical status, underlying pathologic condition, use of other drugs, the type of anesthesia to be used, and surgical procedure involved. Use in the elderly, patients with hepatic or renal disease or in labor requires extra caution (see PRECAUTIONS and INDIVIDUALIZATION OF DOSAGE in full prescribing information). The following are for patients who have not improved hepatic or renal function and who are not on CNS active agents.

Due to the changes in clearance, the mean half-life of butorphanol is increased

NSAIDS

in patients receiving butorphanol

with opioid analgesics.

and incidence of side effects with butorphanol by

In patients taking opioid analgesics chronically, butor-

and reports of overuse and self-reported addiction have been received.

when premedication was administered just before induction of anesthesia. Because of the possibility that a smaller initial dose and longer intervals between doses may be needed. No clinically significant accumulation of butorphanol occurs with concomitant medications that affect hepatic

The effective dosage range, depending on the

termed DELAYED DRUGS.

Although there have been rare reports of infant respiratory distress/apnea following administration of STADOL Injectable for use in the treatment of nonobstructive sleep apnea in adults.

STADOL Injectable (butorphanol tartrate) Injectable should be used during pregnancy in accordance with FDA category C. There are no adequate and well-controlled studies of STADOL (butorphanol tartrate) Injectable in pregnant women beyond 37 weeks of gestation. STADOL should be used during pregnancy only if the potential benefit justifies the potential risk to the infant.

LABOR AND DELIVERED DRUGS

Although there have been rare reports of infant respiratory distress/apnea following administration of STADOL Injectable for use in the treatment of nonobstructive sleep apnea in adults, this adverse effect was not attributed to

STADOL Injectable, as used during controlled clinical trials. The reports of respiratory distress/apnea have been associated with administration of a dose within two hours of delivery. Use of multiple doses, use with additional analgesics or sedative drugs, or use in prematurity pregnancies.

In a study of 119 patients, the administration of 1 mg of IV STADOL Injectable during labor was associ-

a transient decrease in arterial carbon dioxide tension, but was well tolerated with no adverse neonatal outcomes. In the presence of an abnormal fetal heart rate pattern, STADOL Injectable should not be used.

NURSING MOTHERS

Butorphanol has been detected in milk following administration of STADOL (butorphanol tartrate) Injectable to nursing mothers. The amount an infant would receive is probably clinically insignificant (estimated 4 microgram/milk of a mother receiving 2 mg IV every 4 hours during the). In newborn infants, butorphanol is not recommended for use in patients below 18 years of age because safety and effect-

BEHAVIORAL

The most commonly reported adverse experiences across all clinical trials with STADOL Injectable and STADOL NS were somnolence (43%), dizziness (13%), nausea and vomiting (12%), in long-term trials with STADOL NS only, nasal congestion (13%) and insomnia (11%) were frequently reported.

The following adverse experiences were reported at a frequency of 1% or greater, and were consid-

Because of its opioid antagonist properties, butorphanol is not recommended for use in patients

Due to changes in clearance, the mean half-life of butorphanol is increased

and reports of overuse and self-reported addiction have been received.

The occurrence of any side effects with butorphanol by

Factors to be considered in determining the dose are age, body weight, physical status, underlying pathologic condition, use of other drugs, the type of anesthesia to be used, and surgical procedure involved. Use in the elderly, patients with hepatic or renal disease or in labor requires extra caution (see PRECAUTIONS and INDIVIDUALIZATION OF DOSAGE in full prescribing information). The following are for patients who have not improved hepatic or renal function and who are not on CNS active agents.

Due to the changes in clearance, the mean half-life ofbutorphanol is increased

NSAIDS

in patients receiving butorphanol

with opioid analgesics.

and incidence of side effects with butorphanol by

Factors to be considered in determining the dose are age, body weight, physical status, underlying pathologic condition, use of other drugs, the type of anesthesia to be used, and surgical procedure involved. Use in the elderly, patients with hepatic or renal disease or in labor requires extra caution (see PRECAUTIONS and INDIVIDUALIZATION OF DOSAGE in full prescribing information). The following are for patients who have not improved hepatic or renal function and who are not on CNS active agents.

Due to the changes in clearance, the mean half-life ofbutorphanol is increased

NSAIDS

in patients receiving butorphanol

with opioid analgesics.

and incidence of side effects with butorphanol by

Factors to be considered in determining the dose are age, body weight, physical status, underlying pathologic condition, use of other drugs, the type of anesthesia to be used, and surgical procedure involved. Use in the elderly, patients with hepatic or renal disease or in labor requires extra caution (see PRECAUTIONS and INDIVIDUALIZATION OF DOSAGE in full prescribing information). The following are for patients who have not improved hepatic or renal function and who are not on CNS active agents.

Due to the changes in clearance, the mean half-life ofbutorphanol is increased

NSAIDS

in patients receiving butorphanol

with opioid analgesics.